01—Abstract
Summary
Summary of the 10-Q filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported second-quarter 2026 total revenues of $959.0 milliona, up from $687.5 million a year earlier, and net income of $144.4 million, or $1.39 per diluted share, versus $107.5 million and $1.06 in the prior-year quarter.
For the first six months, total revenues were $1,773.5 millionb and net income was $342.3 million, or $3.30 per diluted share. Net product sales of INGREZZA ($716.5 million in the quarter), CRENESSITY ($183.5 million) and the newly acquired VYKAT XR ($54.3 million) drove the results. Selling, general and administrative expense rose to $439.7 million in the quarter, including $96.8 million of acquisition-related expenses for the six months.
The most significant event in the period was the May 18, 2026 acquisition of Soleno Therapeutics, Inc. for $53.00c per share in cash, with preliminary total consideration of $2.83 billion and cash paid, net of cash acquired, of $2.36 billion. The purchase price allocation is preliminary, and the company recognized $2.24 billion of developed product rights for VYKAT XR, with goodwill of $494.6 million. Funding came from cash on hand and sales and maturities of available-for-sale debt securities, and the company also borrowed and then repaid $600.0 million under a new $1.0 billion senior secured revolving credit facility.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $481.7 milliond, down from $2,543.4 million at December 31, 2025, and working capital was $763.0 million. The filing also discloses a Department of Justice civil investigative demand from August 2025 concerning sales and marketing of INGREZZA, which the company is cooperating with, and a securities class action against Soleno that Neurocrine is exposed to as the acquirer. Remaining authorization under the 2025 share repurchase program was $266.3 million at June 30, 2026.
02—Key points
Key Highlights
- Total revenues for the second quarter of 2026 were $959.0 million, up from $687.5 million in the second quarter of 2025; six-month revenues were $1,773.5 million versus $1,260.1 million.
- Net income for the second quarter was $144.4 million ($1.39 diluted EPS), compared with $107.5 million ($1.06) a year earlier; six-month net income was $342.3 million ($3.30 diluted EPS).
- CRENESSITY net product sales were $183.5 million in the quarter versus $53.2 million a year earlier, and INGREZZA net product sales were $716.5 million versus $624.4 million.
- Acquisition of Soleno Therapeutics closed May 18, 2026 at $53.00 per share in cash; preliminary total consideration was $2.83 billion, adding VYKAT XR, with $2.24 billion of intangible assets and $494.6 million of goodwill recognized.
- Acquisition-related costs were significant: $33.1 million of transaction costs, $60.1 million of stock-based compensation settled in cash, and $104.7 million of acquisition-related expenses included in Soleno's post-close results.
- Cash, cash equivalents and marketable securities fell to $481.7 million at June 30, 2026 from $2,543.4 million at December 31, 2025; the $1.0 billion revolving credit facility was undrawn at quarter-end.
- The company disclosed an ongoing U.S. Department of Justice civil investigative demand (August 2025) regarding INGREZZA sales and marketing, with no assurance as to timing or outcome.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 31, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $959.00M$687.50M | +39.5% |
| SG&A Expenses | $439.70M$286.30M | +53.6% |
| Operating Expenses | $807.50M$541.90M | +49.0% |
| Operating Income | $151.50M$145.60M | +4.1% |
| Net Income | $144.40M$107.50M | +34.3% |
| EPS (Basic) | $1.43$1.09 | +31.2% |
| EPS (Diluted) | $1.39$1.06 | +31.1% |
| Shares Outstanding (Basic) | 101.00M99.00M | +2.0% |
| Shares Outstanding (Diluted) | 104.20M101.00M | +3.2% |
05—Questions
Frequently Asked Questions
How did Neurocrine's revenue and profitability change in the second quarter of 2026?
Total revenues rose to $959.0 million from $687.5 million, and operating income increased to $151.5 million from $145.6 million. Net income was $144.4 million, or $1.39 per diluted share, compared with $107.5 million, or $1.06, in the prior-year quarter. The growth was driven mainly by CRENESSITY and INGREZZA net product sales, with the inclusion of VYKAT XR following the Soleno acquisition.
What did Neurocrine pay for Soleno Therapeutics and how was it funded?
Neurocrine paid $53.00 per share in cash, for preliminary total consideration of $2.83 billion, including $2,762.5 million paid to Soleno stockholders and $67.4 million to settle pre-combination equity awards. Cash paid, net of cash acquired, was $2.36 billion. The filing states it was funded from available liquidity, including cash on hand and proceeds from sales and maturities of available-for-sale debt securities.
How much liquidity does Neurocrine have after the acquisition?
At June 30, 2026, total cash, cash equivalents and marketable securities were $481.7 million, compared with $2,543.4 million at December 31, 2025, and working capital was $763.0 million. The company had $1.0 billion of available borrowing capacity under its 2026 Credit Facility, with no borrowings outstanding after repaying $600.0 million in June 2026.
What are the key legal and regulatory matters disclosed?
Neurocrine received a civil investigative demand from the U.S. Department of Justice in August 2025 concerning sales and marketing of INGREZZA and is cooperating; no assurance was given on timing or outcome. The company is also litigating against Zydus over patents covering INGREZZA SPRINKLE, and Soleno, now a Neurocrine subsidiary, faces a putative federal securities class action filed in March 2026. The company believes none of its pending claims is likely to have a material adverse effect.
What share repurchase activity occurred in the period?
During the first six months of 2026, Neurocrine repurchased 0.5 million shares for $66.0 million under the 2025 Repurchase Program. As of June 30, 2026, $266.3 million remained available under that $500.0 million authorization.
06—Continue